Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, the combination of
panobinostat and carfilzomib have on the patient's cancer. It will determine the side effects
of different dose levels of panobinostat and carfilzomib and determine the best dose and
schedule of the two drugs to recommend for future studies. The study will assess the effects
of the drug on multiple myeloma. In addition, tests to study the way the drugs work will also
be done.
The combination of the 2 drug classes have shown both pre-clinical (studies done in the lab)
and clinical (studies done with people) effects against multiple myeloma. For this reason,
these 2 drugs are being studied in combination to determine the side effects and anti-myeloma
effects of the 2 drugs.
Phase:
Phase 1
Details
Lead Sponsor:
Emory University
Collaborators:
Amgen Multiple Myeloma Research Consortium Novartis Onyx Therapeutics, Inc. University of California, San Francisco University of Chicago